Format

Send to

Choose Destination
Cancer Discov. 2019 Jan;9(1):OF2. doi: 10.1158/2159-8290.CD-NB2018-157. Epub 2018 Nov 29.

Mixed Reviews for A2AR Inhibitor in NSCLC.

[No authors listed]

Abstract

Findings of a phase I/II trial of the adenosine 2A receptor blocker NIR178 combined with the PD-1 inhibitor spartalizumab in advanced non-small cell lung cancer suggest that the drugs are safe. Two of 25 patients showed complete or partial responses, and 13 had stable disease.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center